BRCA1 and pachyonychia congenita: Due to the FDAs original approval of olaparib based on the BRCA1/2 status in ovarian cancer, current standard testing does not always include other HR genes, despite the fact that the FDAs approval for olaparib as treatment for castration-resistant PC was based on the findings of the PROfound trail which also included ATM as a predictive biomarker [17].